{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:39:20Z","timestamp":1759451960181,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.vaccine.2020.12.003","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T04:28:19Z","timestamp":1608265699000},"page":"580-587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Heterologous vaccine regimen: Stakeholder acceptance and implementation considerations"],"prefix":"10.1016","volume":"39","author":[{"given":"Helena","family":"Greter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Ivol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Oriol Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9verine","family":"Erismann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Prytherch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4800-3019","authenticated-orcid":false,"given":"Peter","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.12.003_b0005","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: what you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann Med"},{"key":"10.1016\/j.vaccine.2020.12.003_b0010","unstructured":"U.S. Department of Health and Human Services. Vaccine Types. US Department of Health and Human Services; Types of vaccines; 2017."},{"key":"10.1016\/j.vaccine.2020.12.003_b0015","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.smim.2014.10.003","article-title":"Understanding and overcoming the barriers to T cell-mediated immunity against tuberculosis","volume":"26","author":"Urdahl","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2020.12.003_b0020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.12.003_b0025","article-title":"Heterologous prime-boost immunisation regimens against infectious diseases. Defence Science and Technology Organisation Victoria (Australia)","author":"Shahin","year":"2006","journal-title":"Human Protecti Performance Div"},{"key":"10.1016\/j.vaccine.2020.12.003_b0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.it.2003.11.009","article-title":"Jump-starting the immune system: prime-boosting comes of age","volume":"25","author":"Woodland","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.vaccine.2020.12.003_b0035","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jama.2016.20644","article-title":"Immune responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-vectored Ebola vaccines at 1 Year","volume":"317","author":"Winslow","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.12.003_b0040","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.12.003_b0045","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13\u201319)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.12.003_b0050","unstructured":"WHO. Heterologous prime-boost immunisation in Ebola vaccine development, testing and licensure. Report of a WHO Consultation held on 21 November 2014, Geneva, Switzerland. Geneva: World Health Organization; 2014."},{"key":"10.1016\/j.vaccine.2020.12.003_b0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2020.12.003_b0060","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2013.09.061","article-title":"Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys","volume":"155","author":"Barouch","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2020.12.003_b0065","unstructured":"WHO. Overview of the current research, development and use, of vaccines against Ebola. World Health Organization; 2019."},{"key":"10.1016\/j.vaccine.2020.12.003_b0070","doi-asserted-by":"crossref","unstructured":"Giersing BK, Vekemans J, Nava S, Kaslow DC, Moorthy V, WHOPDVAC. Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016. Vaccine 2019;37:7315\u201327.","DOI":"10.1016\/j.vaccine.2016.10.090"},{"key":"10.1016\/j.vaccine.2020.12.003_b0075","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-03-0703","article-title":"Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination","volume":"10","author":"Smyth","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2020.12.003_b0080","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/S0264-410X(01)00086-X","article-title":"Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens","volume":"19","author":"van der Burg","year":"2001","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2020.12.003_b0085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/hec.3303","article-title":"Dynamic transmission economic evaluation of infectious disease interventions in low- and middle-income countries: A systematic literature review","volume":"25","author":"Drake","year":"2016","journal-title":"Health Econ"},{"key":"10.1016\/j.vaccine.2020.12.003_b0090","unstructured":"WHO. Background Paper: programmatic options for implementation of malaria RTS,S vaccination schedule for young children. Geneva: World Health Organization; 2015"},{"key":"10.1016\/j.vaccine.2020.12.003_b0095","unstructured":"WHO. Vaccine introduction guidelines. Adding a vaccine to a national immunization programme: decision and implementation. Geneva: World Health Organization; 2005."},{"key":"10.1016\/j.vaccine.2020.12.003_b0100","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual Health Res"},{"key":"10.1016\/j.vaccine.2020.12.003_b0105","series-title":"Nursing standard (Royal College of Nursing (Great Britain) 1987)","first-page":"32","article-title":"Grounded theory","author":"Harris","year":"1987"},{"year":"2007","series-title":"Qualitative methodology for international public health","author":"Dahlgren","key":"10.1016\/j.vaccine.2020.12.003_b0110"},{"key":"10.1016\/j.vaccine.2020.12.003_b0115","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1016\/j.vaccine.2013.06.041","article-title":"Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors?","volume":"31","author":"Rolnick","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.12.003_b0120","doi-asserted-by":"crossref","unstructured":"Ruffin MTt, Plegue MA, Rockwell PG, Young AP, Patel DA, Yeazel MW. Impact of an Electronic Health Record (EHR) reminder on Human Papillomavirus (HPV) vaccine initiation and timely completion. J Am Board Fam Med. 2015;28:324-33.","DOI":"10.3122\/jabfm.2015.03.140082"},{"key":"10.1016\/j.vaccine.2020.12.003_b0125","first-page":"2113","article-title":"Vaccine adverse events: separating myth from reality","volume":"66","author":"Kimmel","year":"2002","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.vaccine.2020.12.003_b0130","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.clinthera.2017.07.003","article-title":"Vaccine hesitancy: where we are and where we are going","volume":"39","author":"McClure","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2020.12.003_b0135","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0264-410X(00)00358-3","article-title":"Ensuring vaccine safety in immunization programmes \u2013 a WHO perspective","volume":"19","author":"Jodar","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.12.003_b0140","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00038-015-0715-6","article-title":"Exposing concerns about vaccination in low- and middle-income countries: a systematic review","volume":"60","author":"Cobos Mu\u00f1oz","year":"2015","journal-title":"Int J Public Health"},{"key":"10.1016\/j.vaccine.2020.12.003_b0145","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.inhe.2012.07.004","article-title":"Why children are not vaccinated: a review of the grey literature","volume":"4","author":"Favin","year":"2012","journal-title":"Int Health"},{"key":"10.1016\/j.vaccine.2020.12.003_b0150","first-page":"86","article-title":"Vaccine hesitancy, a public health problem","volume":"30","author":"Petrelli","year":"2018","journal-title":"Ann Ig"},{"key":"10.1016\/j.vaccine.2020.12.003_b0155","doi-asserted-by":"crossref","unstructured":"Oyo-Ita A, Wiysonge CS, Oringanje C, Nwachukwu CE, Oduwole O, Meremikwu MM. Interventions for improving coverage of childhood immunisation in low- and middle-income countries. Cochrane Database Syst Rev. 2016;7:CD008145.","DOI":"10.1002\/14651858.CD008145.pub3"},{"key":"10.1016\/j.vaccine.2020.12.003_b0160","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1185\/03007990802085692","article-title":"Factors associated with suboptimal compliance to vaccinations in children in developed countries: a systematic review","volume":"24","author":"Falagas","year":"2008","journal-title":"Curr Med Res Opin"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20315668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20315668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:52:47Z","timestamp":1759402367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20315668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0264410X20315668"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterologous vaccine regimen: Stakeholder acceptance and implementation considerations","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}